The AI-driven Peptide Drug Discovery Platform market refers to the use of artificial intelligence (AI) in the discovery and development of peptide-based drugs. As the AI-driven Peptide Drug Discovery Platform market size is estimated to be around $1.4 billion, the growth outlook for this market is promising, with a market forecast indicating a significant expansion in the industry. The industry expansion is driven by the increasing adoption of AI technologies in the pharmaceutical sector, and the AI-driven Peptide Drug Discovery Platform market is expected to grow at a Compound Annual Growth Rate (CAGR) of 25% from 2026 to 2033. The primary drivers of this growth include the rising demand for personalized medicine, the increasing complexity of drug discovery, and the need for more efficient and effective discovery processes. Key forces shaping the industry include technology shifts, such as the integration of machine learning and natural language processing, regulations, such as the need for compliance with good manufacturing practices, and competitive intensity, with major players investing heavily in AI-driven drug discovery platforms.